790 results on '"HUNT, R. H."'
Search Results
2. Animal models of gastritis: Helicobacter pylori and high-salt diet in the gerbil
3. Role of Helicobacter pylori infection in NSAID-associated gastropathy
4. Helicobacter pylori and Malignant Diseases
5. An overview of Helicobacter pylori epidemiology studies
6. A Clinician’s View of Strategies for Preventing Nsaid-Induced Gastrointestinal Ulcers
7. Helicobacter pylori and dyspepsia: a conceptual approach
8. The Canine Gastric Muscularis Mucosae and Acid Secretion: A Basket Case?
9. The role of acid suppression in the treatment of H. pylori infection
10. Altered physiology of acid secretion in depression-prone Flinders rats results in exacerbated NSAID and stress-induced gastric damage
11. Development of a New Gastric Antisecretory Drug for Clinical Use
12. Refractory Duodenal Ulcer
13. The stomach in health and disease
14. Editorial: towards extended acid suppression – the search continues
15. Editorial: healing of refractory reflux oesophagitis – an ongoing unmet clinical need
16. Commentary: independent risk factors for recurrent neoplasia after endoscopic resection of early gastric cancer
17. Effect of Th1 Cytokines on Acid Secretion in Pharmacologically Characterised Mouse Gastric Glands
18. THE EVOLUTIONARY IMPACT OF LACTOBACILLI ON H. pylori AND GASTRIC ACID SECRETION: DID A CENTURY OF DIETARY CHANGE ALTER THE GASTRIC MICROBIOTA?: Abstract no.: P11.12
19. Rabeprazole extended-release 50 mg compared with esomeprazole 40 mg and rabeprazole delayed release 20 mg
20. The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects
21. Malaria vector composition and insecticide susceptibility status in Guinea Conakry, West Africa
22. Inaccurate endoscopy: a better explanation for placebo-associated endoscopic ulcers: authorsʼ reply
23. Meta-analysis: incidence of endoscopic gastric and duodenal ulcers in placebo arms of randomized placebo-controlled NSAID trials
24. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z
25. Re-analysis of application of haemoclips for non-variceal upper gastrointestinal bleeding data
26. Can global guidelines change health policy?
27. Is an evidence-based approach to creating guidelines always the right one?
28. New algorithm for the treatment of gastro-oesophageal reflux disease
29. Are global guidelines desirable, feasible and necessary?
30. A clinician’s view of strategies for preventing NSAID-induced gastrointestinal ulcers
31. Insecticide resistance in the malarial mosquito Anopheles arabiensis and association with the kdr mutation
32. Review article: the risks of oesophageal acid exposure - from minimal mucosal changes to malignancy
33. Effects of non-steroidal anti-inflammatory drugs on prostaglandin h synthase isoenzyme 2 (cyclo-oxygenase 2) production by porcine gastric mucosa in organ culture
34. Dieldrin resistance in the malaria vector Anopheles gambiae in Ghana
35. Healing rates for moderate and severe oesophagitis
36. Levofloxacin-based rescue regimens after Helicobacter pylori treatment failure: how strong is the evidence?
37. the unmet needs in delayed-release proton-pump inhibitor therapy in 2005
38. Laboratory selection for and characteristics of pyrethroid resistance in the malaria vector Anopheles funestus
39. Mucosal damage during intestinal anaphylaxis in the rat: Effect of betamethasone and disodium cromoglycate
40. Establishment of T-Helper-2 Immune Response Based Gerbil Model of Enteric Infection
41. Should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing
42. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib
43. Acid suppression in healthy subjects following lansoprazole or pantoprazole
44. Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers
45. A randomized controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract
46. Helicobacter pylori and gastric cancer — the cliniciansʼ point of view
47. Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline
48. Reply-The importance of clarithromycin dose in the management of H. pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole
49. PREDICTING TREATMENT FAILURE WITH PPI-BASED TRIPLE THERAPIES IN METRONIDAZOLE-RESISTANT (M-R) H. PYLORI INFECTIONS: A MODEL BASED ON TRIAL META-ANALYSIS DATA
50. IMPACT OF METRONIDAZOLE-RESISTANT (M-R) H. PYLORI STRAINS ON PPI-BASED TRIPLE THERAPIES: A META-ANALYSIS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.